Back to discover
Disease
Connective Tissue Diseases
Late-stage therapeutic developmentEmerging research
1
Publications
16
Clinical trials
2017
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2017-02-01American journal of medical genetics. Part C, Seminars in medical genetics
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q2 2027.
Upcoming Milestones
- Q2 2027Allogenic Adipose Tissue Derived-MSCs Therapy in Patients With Connective Tissue Diseases-associated Interstitial Lung Disease(CTD-ILD): Phase I/IIa Clinical Trial
- Q4 2029An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)
Major developments
Upcoming trial readoutImportant
Results expected Q2 20272026-05-13
Upcoming trial readoutImportant
Results expected Q4 20292025-12-09
Clinical MilestonesViewHide
Results expected
- 2026-05-13Allogenic Adipose Tissue Derived-MSCs Therapy in Patients With Connective Tissue Diseases-associated Interstitial Lung Disease(CTD-ILD): Phase I/IIa Clinical TrialResults expected Q2 2027
- 2025-12-09An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)Results expected Q4 2029
Recently completed
- 2025-12-31A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAHCompleted
- 2025-12-01A Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated ThrombocytopeniaPrimary completion
- 2025-12-01Percutaneous Needle Fasciotomy (PNF) +/- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled TrialPrimary completion
- 2025-11-07A Superiority Study Comparing Two Pharmaceutical Skin Care Creams Containing Different Humectants with a Non-humectant Containing Skin Care Cream for the Treatment of Xerotic Foot of Persons with DiabetesPrimary completion
Other updates
Activity timeline7
- 2026-05-13ClinicalAllogenic Adipose Tissue Derived-MSCs Therapy in Patients With Connective Tissue Diseases-associated Interstitial Lung Disease(CTD-ILD): Phase I/IIa Clinical TrialResults expected Q2 2027
- 2026-03-02ClinicalA Single-center Clinical Study to Evaluate the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue DiseasesWithdrawn
- 2025-12-31ClinicalA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAHCompleted
- 2025-12-09ClinicalAn Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)Results expected Q4 2029
- 2025-12-01ClinicalA Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated ThrombocytopeniaPrimary completion
- 2025-12-01ClinicalPercutaneous Needle Fasciotomy (PNF) +/- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled TrialPrimary completion
- 2025-11-07ClinicalA Superiority Study Comparing Two Pharmaceutical Skin Care Creams Containing Different Humectants with a Non-humectant Containing Skin Care Cream for the Treatment of Xerotic Foot of Persons with DiabetesPrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
16
6
5
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Leading journals1
- American journal of medical genetics. Part C, Seminars in medical genetics1
Leading researchers7
- Berglund B1
- Castori M1
- Cohen H1
- Grahame R1
- Kazkaz H1
- Levy H1
- Tinkle B1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.